aripiprazole has been researched along with Cognitive Dysfunction in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aboul-Fotouh, S; El-Salam, MFA; Elayat, WM; Elhossiny, RM; Habib, MZ; Hassan, GAM; Mohamad, MI; Zohny, SM | 1 |
| Aloi, M; De Fazio, P; de Filippis, R; Gaetano, R; Magliocco, F; Segura-Garcia, C; Staltari, FA | 1 |
| Chakrabarty, T; Frey, BN; Kennedy, SH; Lam, RW; McInerney, SJ; Milev, RV; Müller, DJ; Rotzinger, S; Torres, IJ | 1 |
| Lee, C; Shen, YC | 1 |
| Heo, HJ; Hong, KW; Kim, CD; Kim, HY; Lee, WS; Lee, YS; Park, SY; Shin, HK | 1 |
| Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS | 1 |
| Getova, DP; Topolov, MK | 1 |
| Chen, SF; Shen, YC | 1 |
| Chung, YC; Huang, GB; Lee, KH; Park, CH; Park, MS; Park, TW; Tong, Z; Yang, JC | 1 |
1 review(s) available for aripiprazole and Cognitive Dysfunction
| Article | Year |
|---|---|
Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Dopamine; Humans; Schizophrenia; Schizophrenic Psychology | 2016 |
2 trial(s) available for aripiprazole and Cognitive Dysfunction
| Article | Year |
|---|---|
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Biomarkers; Canada; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Drug Therapy, Combination; Escitalopram; Female; Humans; Male; Middle Aged; Young Adult | 2021 |
No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Dizziness; Double-Blind Method; Female; Haloperidol; Humans; Hypnotics and Sedatives; Male; Neurotoxicity Syndromes; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Severity of Illness Index; Sulpiride; Time Factors; Young Adult | 2012 |
6 other study(ies) available for aripiprazole and Cognitive Dysfunction
| Article | Year |
|---|---|
Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Glutamates; Hippocampus; Homeostasis; Male; Memantine; Pregnancy; Rats; Rats, Wistar; Valproic Acid | 2023 |
Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Delayed-Action Preparations; Executive Function; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Prospective Studies; Schizophrenia | 2020 |
Aripiprazole Improves Psychotic, Cognitive, and Motor Symptoms in a Patient With Lewy Body Dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Humans; Lewy Body Disease; Male; Psychotic Disorders; Tremor | 2017 |
Augmented improvement of cognition and memory by aripiprazole add-on for cilostazol treatment in the chronic cerebral hypoperfusion mouse model.
Topics: Animals; Aripiprazole; Brain; Brain Ischemia; Carotid Stenosis; Cilostazol; Cognition; Cognitive Dysfunction; Dementia, Vascular; Disease Models, Animal; Drug Therapy, Combination; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Spatial Learning | 2019 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2014 |
5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Depression; Female; Humans; Male; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Young Adult | 2017 |